PMID- 38054208
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240123
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 24
DP  - 2023 Dec
TI  - Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in 
      patients with bone and soft tissue sarcomas: A study of the FDA adverse event 
      reporting system joint single-center real-world experience.
PG  - 21709-21724
LID - 10.1002/cam4.6730 [doi]
AB  - OBJECTIVES: To assess the occurrence of cardiotoxicity in patients with tumors 
      receiving anthracycline-based chemotherapy, especially for sarcomas. METHODS: 
      This study summarized the types and frequency of adverse events (AEs) for three 
      anthracyclines from the FDA adverse event reporting system (FAERS) database. 
      FAERS data from January 2004 to June 2022 were collected and analyzed. 
      Disproportionality analyses, logistic regression, and descriptive analysis were 
      used to compare the differences in cardiac disorders. A retrospective cohort 
      study was conducted in a single center between December 2008 and May 2022. Our 
      hospital-treated patients with bone and soft tissue sarcomas (BSTSs) with 
      anthracycline-containing chemotherapy were analyzed. Serum markers, 
      echocardiography, and electrocardiography have been used to evaluate cardiotoxic 
      events. RESULTS: One hundred thousand and seventy-five AE reports were obtained 
      for doxorubicin (ADM), epirubicin (EPI), and liposome doxorubicin (L-ADM) from 
      the FAERS database. ADM (OR = 3.1, p < 0.001), EPI (OR = 1.5, p < 0.001), and 
      sarcomas (OR = 1.8, p < 0.001) may increase the probability of cardiac disorders. 
      Cardiac failure, cardiotoxicity, and cardiomyopathy were anthracyclines' top 3 
      frequent AEs. Among patients receiving ADM-containing therapy, those with ADM 
      applied at doses >/=75 mg/m(2) /cycle were more likely to develop cardiac disorders 
      than the other subgroups (OR = 3.5, p < 0.001). Patients younger than 18 are more 
      likely to benefit from dexrazoxane prevention of cardiac failure. Six hundred and 
      eighty-three patients with BSTSs receiving anthracycline-based chemotherapy were 
      analyzed in our center. Patients receiving ADM-containing chemotherapy were 
      likelier to experience abnormalities in serum troponin-T and left ventricular 
      ejection fraction (p < 0.05). 2.0% (6/300) of patients receiving ADM-containing 
      chemotherapy required adjustment of the chemotherapy regimen because of 
      cardiotoxicity, whereas none were in the EPI or L-ADM groups. CONCLUSIONS AND 
      RELEVANCE: Among patients receiving anthracycline-containing therapy, patients 
      with BSTSs were more likely to develop cardiac disorders than other tumors. In 
      addition, patients with BSTSs receiving ADM chemotherapy had a higher likelihood 
      of cardiotoxic events than those receiving EPI or L-ADM.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Mo, Zeming
AU  - Mo Z
AUID- ORCID: 0000-0002-0476-7618
AD  - Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Deng, Yaotiao
AU  - Deng Y
AD  - Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Bao, Yiwen
AU  - Bao Y
AD  - Department of Oncology, The People's Hospital of Qiannan, Duyun, Guizhou, China.
FAU - Liu, Jie
AU  - Liu J
AUID- ORCID: 0000-0002-6266-4449
AD  - Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Jiang, Yu
AU  - Jiang Y
AUID- ORCID: 0000-0003-0716-4334
AD  - Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
LA  - eng
GR  - 21PJ005/Medical science and technology project of Sichuan Provincial Health 
      Commission/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231206
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 80168379AG (Doxorubicin)
RN  - 3Z8479ZZ5X (Epirubicin)
SB  - IM
MH  - Humans
MH  - Anthracyclines/therapeutic use
MH  - Cardiotoxicity/etiology
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - Antibiotics, Antineoplastic/adverse effects
MH  - *Heart Diseases/chemically induced/diagnosis/epidemiology
MH  - *Heart Failure
MH  - Doxorubicin/therapeutic use
MH  - Epirubicin
MH  - *Sarcoma/drug therapy
MH  - *Soft Tissue Neoplasms/drug therapy
PMC - PMC10757145
OTO - NOTNLM
OT  - ADM
OT  - FDA adverse event reporting system
OT  - anthracyclines
OT  - bone and soft tissue sarcomas
OT  - cardiotoxicity
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/06 06:42
MHDA- 2024/01/02 11:43
PMCR- 2023/12/06
CRDT- 2023/12/06 04:21
PHST- 2023/10/24 00:00 [revised]
PHST- 2023/08/18 00:00 [received]
PHST- 2023/11/07 00:00 [accepted]
PHST- 2024/01/02 11:43 [medline]
PHST- 2023/12/06 06:42 [pubmed]
PHST- 2023/12/06 04:21 [entrez]
PHST- 2023/12/06 00:00 [pmc-release]
AID - CAM46730 [pii]
AID - 10.1002/cam4.6730 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Dec;12(24):21709-21724. doi: 10.1002/cam4.6730. Epub 2023 Dec 6.